BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

KV Pharmaceutical Sues Illinois Over Payment for Drug Makena


8/29/2012 7:19:25 AM

St. Louis Business Journal by Greta Weiderman, Web Editor

KV Pharmaceutical Co. sued the Illinois Department of Healthcare and Family Services to compel the state’s Medicaid program to pay the company more than $500 per injection of KV's Makena drug, instead of just $20 for non-branded versions.

The Bridgeton-based drug company (OTCQB: KVPHA/KVPHB), which filed for Chapter 11 bankruptcy Aug. 4, filed the lawsuit Aug. 21 in U.S. District Court in Chicago, Crain’s Chicago Business reports.

The list price for Makena, which is used to prevent preterm birth, was initially $1,500 per injection, but in April, KV cut the price down 54 percent, to $690, Crain’s reports. To avoid KV’s pricing, some state Medicaid programs are using compounded versions of Makena, which have the same active ingredient as the branded drug and cost $20 per injection.

In the bankruptcy filing, KV Pharmaceutical Co. said federal actions prevented it from getting the “full value” of its Makena medicine to prevent premature births.

The Bridgeton-based drug company listed debts of $728 million and assets of $237 million in its Chapter 11 filing in U.S. Bankruptcy Court in Manhattan.

CEO Greg Divis said in a statement that KV has been unable to realize the full value of its “most important product,” Makena, because of a lack of enforcement of the orphan drug marketing exclusivity granted to KV for the drug by the FDA. “The lack of enforcement has also led certain state Medicaid agencies to impose barriers to access to Makena on low-income pregnant women at high risk for recurrent preterm birth, despite those states’ legal obligation to cover FDA-approved drugs,” he said.

KV Pharmaceutical reported a net loss of $102 million on revenue of $23 million for its fiscal year ended March 31, 2012.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES